Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorNicolaides, C.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorKalofonos, H.en
dc.contributor.authorSamelis, G.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T19:23:54Z
dc.date.available2015-11-24T19:23:54Z
dc.identifier.issn0735-7907-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22383
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntibiotics, Antineoplastic/*therapeutic useen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/mortalityen
dc.subjectDeoxycytidine/administration & dosage/adverse effects/*analogs & derivativesen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectPaclitaxel/administration & dosage/adverse effects/*analogs & derivativesen
dc.subjectPatient Complianceen
dc.subjectSurvival Rateen
dc.subject*Taxoidsen
dc.titleDocetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II studyen
heal.abstractA phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a median performance status of 1 (range, 0-2) were enrolled in the study. Treatment consisted of docetaxel 75 mg/m2 in a 1-hr infusion on day 1 preceded by gemcitabine 1000 mg/m2 over 30 min on days 1 and 8. One hundred eighty-one treatment cycles were administered, 113 (62.4%) of them at full dose. Relative dose intensity of gemcitabine and of docetaxel was 0.73 and 0.85, respectively. More common grade 3-4 toxicities included neutropenia (49%), anemia (10%), fatigue (10%), nausea/vomiting (8%), and alopecia (77%). Seven patients were hospitalized for febrile neutropenia. Granulocyte colony-stimulating factor (G-CSF) administration was required in 90% of patients. Overall, 14 patients (36%) responded, 3 (7.5%) of them completely. Median duration of response was 10.3 months (range, 4.6-17.5+). Median time to progression was 7 months (range, 0.2-17.5+) and median survival 12.7 months (range, 2-20.5+). In conclusion, the combination of docetaxel and gemcitabine, as used in the present study, has moderate activity in anthracycline-resistant ABC. Future studies should incorporate prophylactic administration of G-CSF to reduce the incidence of febrile neutropenia and maintain dose intensity.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10923097-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.3109/07357900009012188-
heal.journalNameCancer Investen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ